A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

NCT03593200 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

PNH

Interventions

DRUG: Pegcetacoplan

Sponsor

Apellis Pharmaceuticals, Inc.